1. Home
  2. BAFN vs CELU Comparison

BAFN vs CELU Comparison

Compare BAFN & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.50

Market Cap

30.9M

Sector

Finance

ML Signal

N/A

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.28

Market Cap

40.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAFN
CELU
Founded
1999
2016
Country
United States
United States
Employees
N/A
123
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
40.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BAFN
CELU
Price
$5.50
$1.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
8.7K
75.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.34%
N/A
EPS Growth
133.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.55
$1.01
52 Week High
$19.00
$4.35

Technical Indicators

Market Signals
Indicator
BAFN
CELU
Relative Strength Index (RSI) 33.77 51.79
Support Level N/A $1.21
Resistance Level $8.26 $1.33
Average True Range (ATR) 0.33 0.11
MACD -0.11 0.01
Stochastic Oscillator 14.21 61.10

Price Performance

Historical Comparison
BAFN
CELU

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: